Advertisement

Quality of Life Research

, Volume 23, Issue 10, pp 2735–2741 | Cite as

Factors associated with quality of life measured by EQ-5D in patients with nontuberculous mycobacterial pulmonary disease

  • Ji Young Hong
  • Sang A. Lee
  • Song Yee Kim
  • Kyung Soo Chung
  • Sung Woo Moon
  • Eun Young Kim
  • Ji Ye Jung
  • Moo Suk Park
  • Young Sam Kim
  • Se Kyu Kim
  • Joon Chang
  • Young Ae KangEmail author
Article

Abstract

Purpose

The impact of pulmonary nontuberculous mycobacterial (pNTM) disease on health-related quality of life (HRQoL) has not received significant attention in the literature. In this study, we compared the HRQoL in patients with pNTM disease and healthy subjects and identified influencing factors using EuroQol 5D (EQ-5D) data.

Methods

The present study used an age- and sex-matched case–control analysis from a cohort of 85 pNTM patients and 340 participants from a national survey. Baseline EQ-5D utility scores and EQ-5D visual analog scale (VAS) scores were measured in both groups. In patients with pNTM disease, the factors affecting EQ-5D were identified using multiple linear regression analysis.

Results

While the median EQ-5D VAS scores were lower in pNTM patients than in the control subjects (pNTM, 70; control, 80; P < 0.001), the median EQ-5D utility scores were similar in two groups (both, 1.000, P = 0.878). Interestingly, the percentage of subjects reporting problems on the anxiety/depression dimension was higher for patients with pNTM disease (18.8 %) compared with the control subjects (11.5 %, P = 0.07). In multivariate analysis, increasing severity of forced expired volume in one second (FEV1) decline was associated with a significant decrease in EQ-5D scores of pNTM patients.

Conclusions

This study suggested the EQ-5D may not be useful instrument in pNTM patients due to ceiling effect of EQ-5D and mild disease activity. Patients with pNTM disease tended to report more reduced health status and more problems with anxiety/depression than the healthy controls. Lung function, measured by FEV1, was independently associated with EQ-5D scores in patients with pNTM disease.

Keywords

Nontuberculous mycobacterium Quality of life EQ-5D 

Notes

Acknowledgments

This work was supported by a National Research Foundation of Korea Grant funded by the Korean Government (2011-0013018).

Conflict of interest

Authors have no conflict of interest including financial, personal, academic and intellectual.

References

  1. 1.
    Prevots, D. R., Shaw, P. A., Strickland, D., Jackson, L. A., Raebel, M. A., Blosky, M. A., et al. (2010). Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. American Journal of Respiratory and Critical Care Medicine, 182(7), 970–976.PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Winthrop, K. L., McNelley, E., Kendall, B., Marshall-Olson, A., Morris, C., Cassidy, M., et al. (2010). Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: An emerging public health disease. American Journal of Respiratory and Critical Care Medicine, 182(7), 977–982.PubMedCrossRefGoogle Scholar
  3. 3.
    Griffith, D. E., Aksamit, T., Brown-Elliott, B. A., Catanzaro, A., Daley, C., Gordin, F., et al. (2007). An official ATS/IDSA statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. American Journal of Respiratory and Critical Care Medicine, 175(4), 367–416.PubMedCrossRefGoogle Scholar
  4. 4.
    Huang, J. H., Kao, P. N., Adi, V., & Ruoss, S. J. (1999). Mycobacterium avium-intracellulare pulmonary infection in HIV-negative patients without preexisting lung disease: Diagnostic and management limitations. Chest, 115(4), 1033–1040.PubMedCrossRefGoogle Scholar
  5. 5.
    Guyatt, G. H., Feeny, D. H., & Patrick, D. L. (1993). Measuring health-related quality of life. Annals of Internal Medicine, 118(8), 622–629.PubMedCrossRefGoogle Scholar
  6. 6.
    Voll-Aanerud, M., Eagan, T. M., Wentzel-Larsen, T., Gulsvik, A., & Bakke, P. S. (2008). Respiratory symptoms, COPD severity, and health related quality of life in a general population sample. Respiratory Medicine, 102(3), 399–406.PubMedCrossRefGoogle Scholar
  7. 7.
    Mehta, M., & Marras, T. K. (2011). Impaired health-related quality of life in pulmonary nontuberculous mycobacterial disease. Respiratory Medicine, 105(11), 1718–1725.PubMedCrossRefGoogle Scholar
  8. 8.
    Glasziou, P., Alexander, J., Beller, E., & Clarke, P. (2007). Which health-related quality of life score? A comparison of alternative utility measures in patients with type 2 diabetes in the ADVANCE trial. Health Qual Life Outcomes, 5, 21.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Sullivan, P. W., Lawrence, W. F., & Ghushchyan, V. (2005). A national catalog of preference-based scores for chronic conditions in the United States. Medical Care, 43(7), 736–749.PubMedCrossRefGoogle Scholar
  10. 10.
    Sim, Y. S., Park, H. Y., Jeon, K., Suh, G. Y., Kwon, O. J., & Koh, W. J. (2010). Standardized combination antibiotic treatment of Mycobacterium avium complex lung disease. Yonsei Medical Journal, 51(6), 888–894.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Lee, H., Park, H. J., Cho, S. N., Bai, G. H., & Kim, S. J. (2000). Species identification of mycobacteria by PCR-restriction fragment length polymorphism of the rpoB gene. Journal of Clinical Microbiology, 38(8), 2966–2971.PubMedCentralPubMedGoogle Scholar
  12. 12.
    Chung, M. J., Lee, K. S., Koh, W. J., Lee, J. H., Kim, T. S., Kwon, O. J., et al. (2005). Thin-section CT findings of nontuberculous mycobacterial pulmonary diseases: Comparison between Mycobacterium avium-intracellular complex and Mycobacterium abscessus infection. Journal of Korean Medical Science, 20(5), 777–783.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Kitada, S., Kobayashi, K., Ichiyama, S., Takakura, S., Sakatani, M., Suzuki, K., et al. (2008). Serodiagnosis of Mycobacterium avium-complex pulmonary disease using an enzyme immunoassay kit. American Journal of Respiratory and Critical Care Medicine, 177(7), 793–797.PubMedCrossRefGoogle Scholar
  14. 14.
    Brooks, R. (1996). EuroQol: The current state of play. Health Policy, 37(1), 53–72.PubMedCrossRefGoogle Scholar
  15. 15.
    Rabin, R., & de Charro, F. (2001). EQ-5D: A measure of health status from the EuroQol group. Annals of Medicine, 33(5), 337–343.PubMedCrossRefGoogle Scholar
  16. 16.
    EuroQol group. (1990). EuroQol: A new facility for the measurement of health-related quality of life. Health Policy, 16(3), 199–208.CrossRefGoogle Scholar
  17. 17.
    Rutten-van Molken, M. P., Oostenbrink, J. B., Tashkin, D. P., Burkhart, D., & Monz, B. U. (2006). Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages? Chest, 130(4), 1117–1128.PubMedCrossRefGoogle Scholar
  18. 18.
    Lee, Y. K., Nam, H. S., Chuang, L. H., Kim, K. Y., Yang, H. K., Kwon, I. S., et al. (2009). South Korean time trade-off values for EQ-5D health states: Modeling with observed values for 101 health states. Value Health, 12(8), 1187–1193.PubMedCrossRefGoogle Scholar
  19. 19.
    van Manen, J. G., Bindels, P. J., Dekker, F. W., Bottema, B. J., van der Zee, J. S., Ijzermans, C. J., et al. (2003). The influence of COPD on health-related quality of life independent of the influence of comorbidity. Journal of Clinical Epidemiology, 56(12), 1177–1184.PubMedCrossRefGoogle Scholar
  20. 20.
    Hayashi, M., Takayanagi, N., Kanauchi, T., Miyahara, Y., Yanagisawa, T., & Sugita, Y. (2012). Prognostic factors of 634 HIV-negative patients with Mycobacterium avium complex lung disease. American Journal of Respiratory and Critical Care Medicine, 185(5), 575–583.PubMedCrossRefGoogle Scholar
  21. 21.
    Khan, Z., Miller, A., Bachan, M., & Donath, J. (2010). Mycobacterium avium complex (MAC) lung disease in two inner city community hospitals: Recognition, prevalence, co-infection with Mycobacterium tuberculosis (MTB) and pulmonary function (PF) improvements after treatment. The Open Respiratory Medicine Journal, 4, 76–81.PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Lee, M. R., Yang, C. Y., Chang, K. P., Keng, L. T., Yen, D. H., Wang, J. Y., et al. (2013). Factors associated with lung function decline in patients with non-tuberculous mycobacterial pulmonary disease. PLoS One, 8(3), e58214.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Oh, E. G., Bang, S. Y., Kim, Y. S., Park, M. S., & Kim, S. K. (2009). Health-related quality of life among Koreans with chronic respiratory disease. The International Journal of Tuberculosis and Lung Disease, 13(5), 580–586.PubMedGoogle Scholar
  24. 24.
    Pickard, A. S., Wilke, C., Jung, E., Patel, S., Stavem, K., & Lee, T. A. (2008). Use of a preference-based measure of health (EQ-5D) in COPD and asthma. Respiratory Medicine, 102(4), 519–536.PubMedCrossRefGoogle Scholar
  25. 25.
    Cook, J. L. (2010). Nontuberculous mycobacteria: Opportunistic environmental pathogens for predisposed hosts. British Medical Bulletin, 96, 45–59.PubMedCrossRefGoogle Scholar
  26. 26.
    Puhan, M. A., Guyatt, G. H., Goldstein, R., Mador, J., McKim, D., Stahl, E., et al. (2007). Relative responsiveness of the Chronic Respiratory Questionnaire, St. Georges Respiratory Questionnaire and four other health-related quality of life instruments for patients with chronic lung disease. Respiratory Medicine, 101(2), 308–316.PubMedCrossRefGoogle Scholar
  27. 27.
    Brazier, J., Roberts, J., Tsuchiya, A., & Busschbach, J. (2004). A comparison of the EQ-5D and SF-6D across seven patient groups. Health Economics, 13(9), 873–884.PubMedCrossRefGoogle Scholar
  28. 28.
    Harper, R., Brazier, J. E., Waterhouse, J. C., Walters, S. J., Jones, N. M., & Howard, P. (1997). Comparison of outcome measures for patients with chronic obstructive pulmonary disease (COPD) in an outpatient setting. Thorax, 52(10), 879–887.PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Szende, A., Leidy, N. K., Stahl, E., & Svensson, K. (2009). Estimating health utilities in patients with asthma and COPD: Evidence on the performance of EQ-5D and SF-6D. Quality of Life Research, 18(2), 267–272.PubMedCrossRefGoogle Scholar
  30. 30.
    Huang, C. T., Tsai, Y. J., Wu, H. D., Wang, J. Y., Yu, C. J., Lee, L. N., et al. (2012). Impact of non-tuberculous mycobacteria on pulmonary function decline in chronic obstructive pulmonary disease. The International Journal of Tuberculosis and Lung Disease, 16(4), 539–545.PubMedCrossRefGoogle Scholar
  31. 31.
    Antonelli-Incalzi, R., Imperiale, C., Bellia, V., Catalano, F., Scichilone, N., Pistelli, R., et al. (2003). Do GOLD stages of COPD severity really correspond to differences in health status? European Respiratory Journal, 22(3), 444–449.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  • Ji Young Hong
    • 1
  • Sang A. Lee
    • 2
  • Song Yee Kim
    • 1
  • Kyung Soo Chung
    • 1
  • Sung Woo Moon
    • 1
  • Eun Young Kim
    • 1
  • Ji Ye Jung
    • 1
  • Moo Suk Park
    • 1
  • Young Sam Kim
    • 1
  • Se Kyu Kim
    • 1
  • Joon Chang
    • 1
  • Young Ae Kang
    • 1
    Email author
  1. 1.Division of Pulmonology, Department of Internal MedicineYonsei University College of MedicineSeoulRepublic of Korea
  2. 2.Graduate SchoolYonsei University College of NursingSeoulRepublic of Korea

Personalised recommendations